MIBG Cardiac Imaging Compared to Ejection Fraction in Evaluation of Cardiotoxicity: a Systematic Review

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2021 Jul 6

PMID 34228328

Citations 1

Authors

Thais Rossato Arrais

Germano Dallegrave Cavalli

Barbara Tietbohl Dos Santos

Gabriela Bartzen Pereira

Celina Borges Migliavaca

Gabriel Blacher Grossman

Andreia Biolo

Affiliations

Soon will be listed here.

Abstract

Background: Advances in diagnosis and treatment of cancer has improved survival but resulted in increased cardiotoxic effects. The decrease in left ventricular ejection fraction (EF), one of the pillars of diagnosis of cardiotoxicity, seems to be a late process in the evolution of the disease, so -metaiodobenzylguanidine (MIBG) cardiac imaging has been proposed to detect early cardiac impairment. The aim of this systematic review was to evaluate the performance of MIBG cardiac scan in this scenario.

Methods And Results: A systematic search was conducted in five international databases comparing MIBG parameters with EF for evaluation of cardiotoxicity. Twelve studies were included and separated in three groups. First, studies evaluating patients with established cardiotoxicity, in which EF was reduced and MIBG parameters were abnormal. Second, studies analyzing patients during or after treatment compared to controls, with MIBG parameters significantly different between groups in most studies, even when EF remained normal. Finally, studies analyzing anthracycline (ATC) dose-related changes, with alteration in MIBG parameters occurring even when EF was preserved.

Conclusion: Although studies had high methodological variability, cardiac sympathetic innervation imaging seems to be a promising tool for assessing early cardiotoxicity. Further studies are needed to analyze its diagnostic value in this scenario.

Citing Articles

Tales from the future-nuclear cardio-oncology, from prediction to diagnosis and monitoring.

Mikail N, Chequer R, Imperiale A, Meisel A, Bengs S, Portmann A Eur Heart J Cardiovasc Imaging. 2023; 24(9):1129-1145.

PMID: 37467476 PMC: 10501471. DOI: 10.1093/ehjci/jead168.

References

Yeh E, Bickford C . Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53(24):2231-47. DOI: 10.1016/j.jacc.2009.02.050. View

Jiji R, Kramer C, Salerno M . Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012; 19(2):377-88. PMC: 3314105. DOI: 10.1007/s12350-012-9512-2. View

Panjrath G, Jain D . Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. J Nucl Cardiol. 2006; 13(3):415-26. DOI: 10.1016/j.nuclcard.2006.03.002. View

Mason J, Bristow M, Billingham M, Daniels J . Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978; 62(6):857-64. View

Cardinale D, Sandri M, Colombo A, Colombo N, Boeri M, Lamantia G . Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109(22):2749-54. DOI: 10.1161/01.CIR.0000130926.51766.CC. View

Cardinale D, Colombo A, Torrisi R, Sandri M, Civelli M, Salvatici M . Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28(25):3910-6. DOI: 10.1200/JCO.2009.27.3615. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Zamorano J, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of.... Eur Heart J. 2016; 37(36):2768-2801. DOI: 10.1093/eurheartj/ehw211. View

Armenian S, Lacchetti C, Barac A, Carver J, Constine L, Denduluri N . Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 35(8):893-911. DOI: 10.1200/JCO.2016.70.5400. View

10.

Ewer M, Ali M, Mackay B, Wallace S, Valdivieso M, Legha S . A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984; 2(2):112-7. DOI: 10.1200/JCO.1984.2.2.112. View

11.

Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick T . Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014; 63(25 Pt A):2751-68. DOI: 10.1016/j.jacc.2014.01.073. View

12.

Oikonomou E, Kokkinidis D, Kampaktsis P, Amir E, Marwick T, Gupta D . Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019; 4(10):1007-1018. PMC: 6705141. DOI: 10.1001/jamacardio.2019.2952. View

13.

Carrio I, Estorch M, Berna L, Tabernero J, Torres G . Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995; 36(11):2044-9. View

14.

Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G . Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med. 1993; 34(9):1503-7. View

15.

Estorch M, Carrio I, Berna L, Alonso C, Germa J, Ojeda B . Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990; 31(12):1965-9. View

16.

Takeishi Y, SUKEKAWA H, Sakurai T, Saito H, Nishimura S, Shibu T . Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging. Ann Nucl Med. 1994; 8(3):177-82. DOI: 10.1007/BF03164994. View

17.

DAmore C, Gargiulo P, Paolillo S, Pellegrino A, Formisano T, Mariniello A . Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol. 2014; 6(7):486-92. PMC: 4109100. DOI: 10.4329/wjr.v6.i7.486. View

18.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S . A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6(7):772-84. DOI: 10.1016/j.jcmg.2013.02.007. View

19.

Sawyer D, Peng X, Chen B, Pentassuglia L, Lim C . Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?. Prog Cardiovasc Dis. 2010; 53(2):105-13. PMC: 2933091. DOI: 10.1016/j.pcad.2010.06.007. View

20.

de Geus-Oei L, Mavinkurve-Groothuis A, Bellersen L, Gotthardt M, Oyen W, Kapusta L . Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med. 2011; 52(4):560-71. DOI: 10.2967/jnumed.110.082784. View